**T****ITLE:**

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells’ Cardiomyogenic Potential

**AUTHORS AND AFFILIATIONS:**

Aida Llucià-Valldeperas1,2, Ramon Bragós3, Antoni Bayés-Genís1,4,5,6

1Insuficiencia Cardiaca y Regeneración Cardiaca (ICREC) Research Program, Health Science Research Institute Germans Trias i Pujol, Badalona, Spain

2Amsterdam Universitair Medisch Centrum (UMC), Vrije Universiteit Amsterdam, Pulmonology and Physiology, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands

3Electronic and Biomedical Instrumentation Group, Departament d’Enginyeria Electrònica, Universitat Politècnica de Catalunya, Barcelona, Spain

4Cardiology Service, Germans Trias i Pujol University Hospital, Badalona, Spain

5Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

6Centro de Investigación Biomédica en Red (CIBER) Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain

**Corresponding Author:**

Aida Llucià-Valldeperas (a.lluciavalldeperas@vumc.nl)

**Email Addresses of Co-authors:**

Ramon Bragos (rbb@eel.upc.edu)

Antoni Bayés-Genís (abayes.germanstrias@gencat.cat)

**KEYWORDS:**

Electromechanical stimulation; electrical stimulation; mechanical stimulation; electromechanical system; cardiac progenitor cells; cardiac ATDPCs; cell conditioning; cardiac tissue engineering; cell maturation; disease modeling; drug screening

**SUMMARY:**

Here we present a protocol for training a cell population using electrical and mechanical stimuli emulating cardiac physiology. This electromechanical stimulation enhances the cardiomyogenic potential of the treated cells and is a promising strategy for further cell therapy, disease modeling, and drug screening.

**ABSTRACT:**

Cardiovascular diseases are the leading cause of death in developed countries. Consequently, the demand for effective cardiac cell therapies has motivated researchers in the stem cell and bioengineering fields to develop *in vitro* high-fidelity human myocardium for both basic research and clinical applications. However, the immature phenotype of cardiac cells is a limitation on obtaining tissues that functionally mimic the adult myocardium, which is mainly characterized by mechanical and electrical signals. Thus, the purpose of this protocol is to prepare and mature the target cell population through electromechanical stimulation, recapitulating physiological parameters. Cardiac tissue engineering is evolving toward more biological approaches, and strategies based on biophysical stimuli, thus, are gaining momentum. The device developed for this purpose is unique and allows individual or simultaneous electrical and mechanical stimulation, carefully characterized and validated. In addition, although the methodology has been optimized for this stimulator and a specific cell population, it can easily be adapted to other devices and cell lines. The results here offer evidence of the increased cardiac commitment of the cell population after electromechanical stimulation. Electromechanically stimulated cells show an increased expression of main cardiac markers, including early, structural, and calcium-regulating genes. This cell conditioning could be useful for further regenerative cell therapy, disease modeling, and high-throughput drug screening.

**INTRODUCTION:**

Heart function is based on the coupling of electrical excitation and mechanical contraction. Briefly, cardiomyocyte intercellular junctions permit electrical signal propagation to produce almost synchronous contractions of the heart that pump blood systemically and through the pulmonary system. Cardiac cells, thus, undergo both electrical and mechanical forces that regulate gene expression and cellular function. Accordingly, many groups have attempted to develop culture platforms that mimic the cardiac physiological environment to understand the role of mechanical and electrical stimulation on cardiac development, function, and maturation. *In vitro* electrical and mechanical stimulations individually have been applied extensively in cardiac tissue engineering to enhance functional properties, increase cell maturation, or improve cell–cell coupling and calcium handling1-21. Nevertheless, synchronous electromechanical conditioning remains unexploited because of the challenge of developing a stimulator and protocol, and because of the mandatory optimization22.

Preliminary work addressed electromechanical stimulation as a combination of electrical stimulation and media perfusion; however, the flow does not involve the strain-based deformation typical of ventricular filling23-25. Later, more physiological approaches combined electrical stimuli with physical deformation or stretch to mimic the isovolumetric contraction26-31. Feng *et al.* described the first demonstration of electromechanical stimulation in 2005, reporting enhanced cardiomyocyte size and contractile properties26. Wang *et al.* pretreated mesenchymal stem cells with 5-azacytidine and applied simultaneous electrical and mechanical conditioning, improving recellularization, cell viability, cardiac differentiation, and tissue remodeling27. Since those publications, more groups have reported on electromechanical stimulation of cell monolayers or engineered tissues (*e.g.*, Black28, Vunjak-Novakovic29,31, and our group30) with the first conditioned cells tested *in vivo*30. Briefly, Morgan and Black tested several combinations of electrical and mechanical stimuli, reporting that the timing between stimulations was crucial because delayed combined electromechanical stimulation yielded the best results28. Next, Godier-Furnémont and collaborators optimized an electromechanical stimulation protocol for engineered heart muscle constructs from neonatal rat heart cells and achieved, for the first time, a positive force–frequency relationship29. Afterward, our group reported that electromechanically preconditioned cells increased the expression of main cardiac markers *in vitro* and broad beneficial effects *in vivo*, such as improved cardiac function or increased vessel density in the infarct border region30. The most recent publication demonstrated that cardiac tissues from stem-cell-derived cardiomyocytes subjected to electromechanical conditioning reached a maturation level closer to human adult cardiac structure and function31. Additionally, alternative three-dimensional stimulation platforms comprise electroactive scaffolds that provide electrical, mechanical, and topographical cues to the cells attached32. Moreover, mechanical deformation (cell monolayer stretching and compression) can also be induced with stretchable electrodes mimicking normal physiological conditions, as well as extreme conditions33.

Therefore, the rationale is that *in vitro* electromechanical stimuli based on physiological conditions could enhance the cardiomyogenic potential of a cell. Indeed, this stimulation could benefit further integrations of therapeutic cells into the myocardium in a clinical scenario or increase tissue maturation for drug-screening applications.

In addition, we isolated and characterized a population of human adipose tissue-derived progenitor cells of cardiac origin (cardiac ATDPCs)34. These cells are located in the epicardial fat. These cells display beneficial histopathological and functional effects in the treatment of myocardial infarction and also maintain cardiac and endothelial differentiation potential.30,35. We hypothesized that these benefits would increase after biophysical stimulation.

Consequently, we developed a device and a stimulation regime for the cell population of interest and investigated the effects. This electromechanical protocol is a new strategy to induce active cell stretching in a sterile manner and noninvasively compared to previous publications36, in combination with electric field stimulation. The technique reported here explains in detail the device and method used for the electrical, mechanical, and electromechanical stimulation of cells.

This device can provide both electrical and mechanical stimulation, independently or simultaneously. The stimulation is performed with a noninvasive and aseptic novel approach that includes presterilized cell support, electrodes placed inside a standard culture plate, and a platform that induces the mechanical and electrical forces (**Figure 1**).

The platform can hold up to six culture plates and consists of a sandwich structure of laser-cut poly(methyl methacrylate) and printed circuit-board pieces. The platform prototype relies on a combination of a monophasic programmable computer-controlled electrical stimulator, a printed circuit board for the robust connection of the electrodes, and six 10 mm x 10 mm x 5 mm nickel-plated neodymium-fixed magnets placed near one side of the culture plates. There is also an aluminum bar with six driving magnets (same model) placed in front of the other side of the culture plates and moved with a linear servomotor. The motor is driven by a motor controller, operated through an RS-232 port by commercial software (see the **Table of Materials**). Through the user interface and programmable stimulator, it is possible to program the electrical intensity, the pulse duration and frequency, the frequency of mechanical stimulation, its duty cycle, the number of pulses, the pulse amplitude (magnet excursion), and the slope.

[Place **Figure 1** here.]

Both the stimulator and the method for electromechanical conditioning are fully described in two international patents, WO-2013185818-A137 and WO-2017125159-A138.

The biocompatible silicone constructs designed to provide structural support to cells, electrodes, and magnets have been described previously10,21. Briefly, they consist of polydimethylsiloxane (PDMS), molded and cured at room temperature, with a Young’s modulus of 1.3 MPa, close to physiological levels. The construct contains a cell culture pool in a flexible area (10 mm x 10 mm x 2 mm), two inner transverse slots to hold the electrodes, and two embedded 6 mm x 2 mm x 4 mm nickel-plated neodymium magnets. The electrodes are built with 0.2 mm platinum wire twisted around a 2 mm x 3 mm x 12 mm polytetrafluoroethylene (PTFE) core bar (21 cm per electrode, approximately 23 turns) and placed at opposite sides of the flexible area to create an electric field for inducing electrical stimulation. Mechanical stretching is achieved through magnetic attraction between magnets embedded in the support and external magnets placed next to the culture plate and on the moving aluminum arm. In this way, the cell support can be extended without breaking the sterile barrier. This approach is suitable for a cell monolayer but could be adapted to three-dimensional constructs, as well.

In addition, a regular pattern could be imprinted where the cells are seeded, using a ruled diffraction grating (1,250 grooves/mm). The direct visualization of cells cultured on the PDMS construct under brightfield and fluorescent microscopes is possible because of its transparency and 0.5 mm thickness. In the current case, the PDMS culture pool has a vertical surface pattern, perpendicular to the stretching force, to align the cells perpendicularly to the electric field, which minimizes the electric field gradient across the cell.

**Figure 1** shows a detailed description of the construct and device used for the stimulation. The PDMS construct and characteristics are optimized for cell stretching (**Figure 1A,B**). The stimulator is developed and validated for the effective application of the desired electrical and mechanical stimulation to cells attached to the PDMS construct. This process includes ensuring good connectivity and user operability through the software interface (**Figure 1C,D**).

The procedure for cell stimulation using this custom-made device is described in the protocol section.

**PROTOCOL:**

This study uses human cardiac ATDPCs from patient samples. Their use has been approved by the local ethics committee, and all patients gave informed consent. The study protocol conforms to the principles outlined in the Declaration of Helsinki.

1. **Preparations**
   1. Autoclave two tweezers, 12 platinum PTFE electrodes for electrical stimulation, and some paper towels, at 121 °C for 20 min.
   2. Sterilize 12 PDMS custom-made constructs (**Figure 1A**).
      1. Wash each construct with 5 mL of sterile, distilled water with magnetic agitation at room temperature for 15 min.
      2. Wash 1x with 5 mL of 70% ethanol with magnetic agitation at room temperature for 5 min.
      3. Wash 5x with 5 mL of sterile, distilled water with magnetic agitation at room temperature for 10 min per wash, to remove alcoholic residues.
      4. Dry the constructs on sterile paper towels inside the flow cabinet overnight.
      5. Store them in sterile 50 mL centrifuge tubes until use.
2. **Cell Seeding (Day -1)**
   1. Before cell seeding, transfer the cleaned PDMS constructs to sterile plates and expose them to ultraviolet light for 5 min to ensure complete sterilization.
   2. Transfer each construct to a 35 mm cell culture plate for immediate cell seeding.
   3. Trypsinize a confluent T75 flask of cardiac ATDPCs.
      1. Wash the T75 flask with 5 mL of 1x phosphate-buffered saline (PBS).
      2. Add 1 mL of 0.05% trypsin-EDTA and incubate at 37 °C for 5 min to detach the cells.
      3. Add 5 mL of complete medium to inactivate the trypsin-EDTA.
      4. Collect all cells in a 15 mL tube and wash the flask 2x with 5 mL of PBS to collect any remaining cells.
      5. Centrifuge at 230 x *g* for 5 min at 22 °C, remove the supernatant, and resuspend the cells in 2 mL of complete medium to count them with the hemocytometer chamber.
   4. Seed 200 µL of cardiac ATDPCs (2.5 x 105 cells/mL) into the cell pool of the 12 PDMS constructs (**Figure 1A,B**) to have ~80% of the seeding surface covered by cells the day after, and incubate at 37 °C and 5% CO2.

NOTE: After 2 - 4 h, the cells should be attached. Cell inoculum is prepared according to the cell size and growth. For smaller cells, the seeding density should be increased.

* 1. Gently add 2 mL of prewarmed complete medium (α-MEM supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin–streptomycin) per plate.
  2. Incubate the constructs at culture conditions (usually 37 °C and 5% CO2) overnight.

1. **Electromechanical Stimulation Setup (Day 0)**
   1. Before starting the procedure, take six constructs for electromechanical stimulation and six as nonstimulated controls. With fewer than six plates per stimulation, use empty constructs with the same medium volume to ensure proper electric field stimulation.
   2. Clean the stimulation unit with 70% ethanol and place it in the flow cabinet.
   3. Bring the sterile electrodes and tweezers inside the flow cabinet.
   4. Remove 90% of the media from the culture plate to easily manipulate the electrodes and constructs. First, place the PDMS constructs in the right position to ensure magnetic attraction (PDMS displacement within the culture plate toward the magnet) between both fixed and mobile magnets. Next, connect the platinum wire to the electrode connectors and the PTFE part in its designated space in the PDMS construct.
   5. Add 2.5 mL of fresh prewarmed complete medium to each construct.

NOTE: Maintain the sterility throughout the procedure and operate on one construct at a time. Maintain the rest of the constructs in the incubator at 37 °C and 5% CO2 until use.

* 1. Once all PDMS constructs are placed and electrically connected to the platform, bring the platform back into the incubator at 37 °C and 5% CO2.
  2. Connect the electrical and mechanical source.
  3. Configure the stimulation program. Specify electrical and mechanical stimulation regimes through the user interfaces of the electrical stimulator and the application, which controls the mechanical stimulation.Set the synchronism as follows.
     1. Switch on the electrical stimulator. Wait for the main menu to appear in the display.
        1. Then, select **Option 2: Edit sequence + Enter**.
        2. Edit the sequence **Menu** as follows.
           1. Use the **Mode** tab to select either voltage or current. Select current by clicking **+** and press **Enter**.
           2. For the **Amplitude** tab, select **1 (mA)** with **+/-** and press **Enter.**
           3. For the **Period (T)**, select **1000 (ms)** with **+/-** and press **Enter**.
           4. Set the **Pulse duration (Tw)** to 2 **(ms)** with **+/-** and press **Enter**.
           5. For the **Trigger mode** tab, select **External by software** and press **Enter**.
           6. Back in the main menu, select **Option 4: Generate sequence** and press **Enter**.

NOTE: The electrical stimulator rests in the standby until it receives a trigger command from the mechanical stimulator application through the serial port.

* + 1. Perform the following steps in the mechanical stimulation section of the control application panel (**Figure 2C**).
       1. Write 1000 (ms) in the **Pulse Period** text control.
       2. Write 500 (ms) in the **ON time (Tw)** text control to set the mechanical pulse duration.

* + - 1. Write 2000 (AU) in the **Excursion** text control to deliver a 10% construct elongation. This is the number of steps in the linear control motor.

NOTE: The stimulation protocol applied here consists of alternating-current 2 ms monophasic square-wave pulses of 50 mV/cm at 1 Hz and 10% stretching for 7 days. The rise and fall times of the mechanical pulse are set at 100 ms, to roughly imitate the shape of the hearth pressure pulse. Also, the repetition mode is set to **Continuous** and there is a counter displaying the number of pulses.

* 1. Change the media 2x a week (Monday and Thursday afternoon). First, remove the old media; next, add the warm media on the sides of the PDMS support, never directly on the cell pool.

NOTE: If the cells have a high growth rate, the media should be changed 3x a week (*e.g.*, Monday, Wednesday, and Friday). It is necessary to disconnect and reconnect all cables, but there is no need to remove the culture plates and electrodes from their place.

* 1. Collect the samples after the experimentation is performed.

1. **Sample Collection at the End of the Experimentation (Day 7)**
   1. **For RNA analyses**
      1. Wash the construct 2x with 3 mL of 1x PBS for 5 min at room temperature.
      2. Add 3 mL of 0.05% trypsin-EDTA to each plate (enough to cover the whole construct) and wait for 5 min at 37 °C.
      3. After the cells are detached, add 2 mL of complete medium to inactivate the trypsin-EDTA.
      4. Collect all cells in a 15 mL tube and wash the construct 2x with 3 mL of PBS to collect any remaining cells.
      5. Centrifuge at 230 x *g* for 5 min at 22 °C.
      6. Remove the supernatant and resuspend the pellet in 1 mL of PBS.
      7. Transfer the cell solution to a 1.5 mL tube and centrifuge at 230 x *g* for 5 min.
      8. Remove the supernatant and store the pellet at -80 °C in 700 μL of lysis reagent for further RNA isolation.
      9. Isolate RNA using a commercial kit, following the manufacturer’s instructions.
      10. Reverse-transcribe the isolated RNA using the kit and random hexamers, according to the manufacturer’s protocol.
      11. For small RNA concentrations, preamplify and, then, dilute 1:5 with RNase-free water before subsequent real-time reverse transcription polymerase chain reaction (RT-PCR) is performed. Continue with the standard protocol for real-time RT-PCR and check main cardiac markers.

NOTE: Typical cardiac markers comprise early and late markers from different categories, such as cardiac transcription factors (myocyte-specific enhancer factor 2A [MEF2A], GATA-binding protein 4 [GATA-4]) and structural (cardiac troponin I [cTnI], cardiac troponin T [cTnT], α-actinin) and calcium regulation (Connexin43 [Cx43], sarco-/endoplasmic reticulum Ca2+-ATPase [SERCA2])30. Protein isolation can also be performed if needed. Simultaneous RNA and protein isolation can be performed with the same sample, using commercially available reagents and kits (**Table of Materials**) if the sample quantity is less.

* 1. **For immunostainings**

NOTE: This is performed directly on the cells attached to the cell pool of the PDMS construct. Therefore, we recommend placing, every time, 1 cm x 1 cm of paraffin film on the top of the cell pool, apart from the plate lid, to minimize the evaporation of the incubation solutions.

* + 1. Wash the construct 2x with 3 mL of PBS for 5 min at room temperature.
    2. Fix the cells attached to the construct with 2 mL of 10% formalin for 15 min at room temperature.
    3. Wash the cells 3x with 3 mL of PBS for 5 min at room temperature. For long-term storage, leave the samples in PBS with 0.1% sodium azide at 4 °C.
    4. Permeabilize the cells with 3 mL of PBS + 0.5% detergent (3x, each time 5 - 10 min, at room temperature).
    5. Incubate the cells with 100 μL of PBS + 10% horse serum + 0.2% detergent + 1% bovine serum albumin at room temperature for 1 h, to block nonspecific antibody binding.
    6. Incubate the cells with 100 μL of PBS + 10% horse serum + 0.2% detergent + 1% bovine serum albumin + primary antibody at room temperature for 1 h. For example, primary antibodies against Cx43 (1:100), sarcomeric α-actinin (1:100), GATA-4 (1:50), MEF2 (1:25), and SERCA2 (1:50).
    7. Wash 3x with 3 mL of PBS at room temperature for 5 min.
    8. Incubate the cells with 100 μL of PBS + secondary antibody at room temperature in the dark for 1 h.

NOTE: Secondary antibodies conjugated with different fluorophores and a counterstaining agent were used.

* + 1. Wash them 3x with 3 mL of PBS at room temperature in the dark for 5 min.
    2. Incubate the cells with 100 μL of nuclear staining (0.1 μg/mL) in PBS at room temperature in the dark for 15 min.
    3. Wash them 3x with 3 mL of PBS at room temperature in the dark for 5 min.
    4. Store the samples in 3 mL of PBS with 0.1% sodium azide at 4 °C until the acquisition.

NOTE: Microscope acquisition is possible on inverted fluorescent and confocal microscopes with long-working distance objectives because the construct thickness is about 0.5 mm.

**REPRESENTATIVE RESULTS:**

**Figure 2** represents the general schema followed for the cell stimulation. Briefly, cells were seeded on the PDMS construct and subjected to electromechanical stimulation, with a media change performed twice a week. Nonstimulated cells were used as a control for the electromechanical conditioning. Additionally, we added an extra control to the experiment, and subcutaneous ATDPCs were used as a control for cardiac ATDPCs. Subcutaneous ATDPCs are obtained from subcutaneous adipose tissue, following the same isolation and culture procedures as for cardiac ATDPCs33. Cells attached to the PDMS construct evidenced a typical fusiform phenotype before and after stimulation. Moreover, the cells aligned according to the patterned surface, in this case following the vertical pattern.

Electrical and mechanical stimulations were first optimized individually. First, electrostimulation was based on a previous study in which alternating-current 2 ms monophasic square-wave pulses of 50 mV/cm at 1 Hz were found to be best for cardiac ATDPCs10. We reported that electrical stimulation increased the expression of early cardiac markers in cardiac ATDPCs, such as MEF2A (*P* = 0.050) and GATA-4 (*P* = 0.031), but no effects on structural and calcium-handling genes were observed (data not shown).

Second, the mechanostimulation protocol consisted of 10% stretching and a 1 Hz trapezoidal waveform with a 50% duty cycle, with 100 ms rise and fall times to imitate the pressure cycle in the heart, as described in full before21. Mechanically stimulated cardiac ATDPCs augmented the expression of structural genes, such as α-actinin (*P* = 0.001) or cTnI (*P* = 0.044), and showed an increasing trend for early cardiac markers, GATA-4 (*P* = 0.068) and T-box transcription factor 5 (Tbx5; *P* = 0.065) (data not shown). Effects derived from mechanical stimulation were strongly dependent on the patterned surface.

Afterward, both protocols were combined for an efficient electromechanical stimulation of cardiac ATDPCs, resembling ventricle-filling by blood. The resulting protocol comprised alternating-current 2 ms monophasic square-wave pulses of 50 mV/cm at 1 Hz and 10% stretching for 7 days30. Overall, electromechanically stimulated cardiac ATDPCs enhanced their cardiomyogenic potential. Stimulated cardiac ATDPCs increased the expression of early and late cardiac genes (**Figure 3A**), namely, the cardiac transcription factor GATA-4 (*P* = 0.050), the structural marker β-myosin heavy chain (β-MHC; *P* = 0.000), and the calcium-related gene Cx43 (*P* = 0.025). Gene modulations resulting from the electromechanical stimulation were also translated at the protein level (**Figure 3B-M**). Phalloidin staining against actin fibers showed that the majority of cells aligned according to the vertical pattern and that the Cx43 distribution was mostly in the cytoplasm and at the plasma membrane, to contribute to intercellular communication through gap junctions (**Figure 3B-E**). MEF2 and GATA-4 transcription factors were located at the nuclei in cardiac ATDPCs; however, GATA-4 was not detected in subcutaneous ATDPCs (**Figure 3F-M**). The cytoplasmic markers SERCA2 and sarcomeric α-actinin did not show a mature sarcomere organization typical for cardiomyocytes, and beating was not observed in control and stimulated cell populations (**Figure 3F-M**).

**FIGURE LEGENDS:**

**Figure 1:** **Electromechanical stimulator.** (**A**) PDMS construct used for the cell conditioning. (**B**) Drawing of the PDMS construct, including electrodes and magnets. (**C**) Detail of the printed circuit board (platform) used to perform the electromechanical conditioning. This panel has been modified from Llucià-Valldeperas *et al.*30. (**D**) Picture of the electromechanical stimulation platform and user interface (computer).

**Figure 2:** **Electromechanical stimulation procedure, unit, and user interface.** (**A**) Electromechanical stimulation schema with representative images of nonstimulated cells at day 0 and stimulated cells at day 7, both on constructs with the vertical surface pattern. The scale bars = 100 μm. (**B**) Electromechanical stimulation unit: seeded PDMS construct, electrodes, and fixed/mobile magnets. (**C**) Control application panel for the mechanical stimulation.

**Figure 3:** **Gene and protein expression of the main cardiac markers after the electromechanical stimulation of cardiac and subcutaneous ATDPCs.** (**A**) Real-time PCR of main cardiac genes in cardiac and subcutaneous ATDPCs. The relative expression of cardiomyogenic markers in stimulated *versus* nonconditioned controls is shown for cardiac and subcutaneous ATDPCs. Values were normalized to glyceraldehyde-3-phosphate dehydrogenase expression and are shown as mean ± SEM for six independent experiments. \* *P* < 0.05 (significance). (**B** - **M**) Protein expression in cardiac and subcutaneous ATDPCs on a vertical-patterned surface expression of main cardiac markers for control and stimulated cells. Phalloidin staining (actinF; red) and Cx43 expression (green), SERCA2 (red), MEF2 (green), sarcomeric α-actinin (red), and GATA-4 (green) expression in control (in panels **B**, **D**, **F**, **H**, **J**, and **L**) and stimulated (in panels **C**, **E**, **G**, **I**, **K**, and **M**) cardiac (left) and subcutaneous (right) ATDPCs. Nuclei were counterstained with DAPI (blue; panels **B** - **E**, **L**, and **M**). The scale bars = 50 μm. This figure has been modified from Llucià-Valldeperas *et al.*30.

**DISCUSSION:**

Electromechanical stimulation appears to be a safe alternative for preparing cells for a hostile cardiac environment and enhancing their cardiac commitment. Here, a protocol described for cardiac progenitor cells increased the expression of main cardiac markers and was reported to be beneficial for their next implantation on infarcted murine myocardium30. In general, electromechanically stimulated cardiac ATDPCs increased the expression of genes related to early, structural, and calcium regulation, which has never been achieved with previous electrical or mechanical stimulations individually. In fact, electromechanically stimulated cardiac ATDPCs show a more complete profile and seemed to be more committed to the cardiac lineage than previously reported.

Cardiac gene expression was modulated in both cell types after electromechanical stimulation, especially after the notable augmentation of cardiac ATDPCs compared to subcutaneous ATDPCs. This result may have been a consequence of the origin of the adipose tissue used for cell isolation, namely, epicardial or subcutaneous fat, respectively. The epicardial adipose tissue surrounding both heart and pericardium is a metabolically active organ and a source of progenitor cells. Of interest, the epicardial fat has anatomical and functional continuity with the myocardium. Under normal circumstances, the epicardial fat has biochemical and thermogenic cardioprotective properties; conversely, under pathological conditions, it can secrete proinflammatory cytokines to affect the heart39. Indeed, cardiac ATDPCs have an inherent cardiac-like phenotype and exhibit a constitutive expression of cardiac markers, such as Cx43, sarcomeric α-actinin, SERCA2, and GATA-4, compared to subcutaneous ATDPCs, which are not that adapted to the cardiac environment34. Thus, effects derived from electromechanical stimulation might be greater for cardiac progenitor cells, whose niche is close to or within the myocardial milieu.

From the last observation in which gene modulation strongly depends on the cell population, a protocol optimization for each cell population is advisable, and approximate values can be extracted from those described in this protocol. The most critical steps in cell electromechanical stimulation are cell attachment and stimulation regimes (intensity, duration, frequency).

For example, the electric parameters are crucial. Indeed, the electric field intensity applied was optimal for a nonelectric cell, so increased values would be more appropriate for cells with electrical activity, such as immature pluripotent stem-cell-derived cardiomyocytes40,41. Preliminary experimentation for cardiac ATDPC electrostimulation demonstrated that a direct current and a high voltage induced cell growth arrest and cell death10. From these results, alternating-current and low-voltage protocols were adopted for further experimentation.

Additionally, some cell lineages present a low attachment to the PDMS surface, so a coating or a plasma treatment is suggested to enrich the seeding efficiency42. Moreover, cell seeding should be adapted to each cell size and growth, decreasing the values for the highly proliferative cells or increasing them for smaller cells; thus, a few trials seeding several densities on the PDMS construct are recommended. Finally, the protocol was performed on a cell monolayer, and values may be slightly different for a three-dimensional scenario (*i.e.*, the cell density).

Furthermore, the surface pattern plays a key role in mechanical cell training. It was shown that the cells aligned according to the pattern, and their performance after mechanical stimulation was not the same among different surfaces. For instance, mechanically stimulated cardiac ATDPCs seeded on vertical-patterned surfaces (perpendicular to the stretching force) secreted proteins associated with myocardial infarction and extracellular matrix remodeling motifs. Mechanostimulated cardiac ATDPCs seeded on nonpatterned surfaces secreted proteins associated with cardiac regeneration21.

The main features of this method have been described above. However, it is important to highlight the noninvasive approach of the cell stretching as one of the unique methods to achieve these features. Of interest, because the same device can submit electrical and/or mechanical stimuli, a direct comparison of the resulting effects from different stimulations and cells is possible. In addition, the visualization of the cells seeded on the construct, thanks to transparency and thinness, is a clear advantage to evaluate cell status before, during, and after stimulation.

The device and the protocol have some limitations, some of them already noted. First, it was designed and optimized for a monolayer cell culture and not for a three-dimensional cell culture. Specifically, only adherent cells can be used in the monolayer setting. For nonadherent cells, a three-dimensional approach should be implemented. Second, the construct size limits the seeding surface; thus, the number of stimulated cells is small, and every experimental set requires several replicates to collect enough samples for further gene or protein analyses. A scale-up is mandatory for large animal experimentation or clinical translation, in which higher cell doses are required; in such cases, bigger stimulation surfaces can be considered.

The main applications of this protocol include cell conditioning, disease modeling, and drug screening. This stimulation enhances cell maturation, and its application would be useful for achieving and maintaining a more mature phenotype. On one hand, cells that mimic the functional phenotype present in the adult myocardium are crucial for disease modeling and organ-on-a-chip experimentation. Indeed, human biopsies cannot represent the progression of the disease because they are usually end-stage or post-mortem samples, while animal models do not always recapitulate human physiology and symptomatology. Nevertheless, the use of human-induced pluripotent stem cells has emerged as an alternative modeling method for unraveling the mechanism underlying pathology development43. In addition, organs-on-a-chip are miniature tissues and organs grown *in vitro* that allow the modeling of human (patho)physiology and mimic the three-dimensional structures. Their aim is to establish a minimally functional unit that can recapitulate certain aspects of human physiology and disease in a controlled and straightforward manner and address the limitations of existing cell and animal models44.

On the other hand, drug screening requires culture platforms that mimic the biophysical environment present *in vivo* in a high-throughput, miniaturized system for testing the safety and efficacy of drugs *via* cardiomyocyte response. Mature cells could be used to recapitulate a clinically relevant readout (*i.e.*, contractile kinetics) in a high-throughput assay, to elucidate disease mechanisms and identify novel therapeutic targets45.

The cardiac field was the main scope of this protocol, but it could easily be adapted to neuronal or skeletal domains because these environments are characterized by electrical and mechanical stimuli. Previous studies with physical stimulations have indicated beneficial outcomes46-50.

In conclusion, a new protocol for the synchronous electromechanical conditioning of cardiac ATDPCs has been described. The resulting protocol and device have been extensively tested and validated for individual and synchronized stimuli. Synchronous electromechanical conditioning of ATDPCs boosts their cardiomyogenic potential and emerges as a promising strategy for cell therapy, disease modeling, and drug screening.

**ACKNOWLEDGMENTS:**

The authors want to thank the members of the ICREC Research Program (IGTP, Badalona) and the Electronic and Biomedical Instrumentation Group (UPC, Barcelona), especially Prof. J. Rosell-Ferrer. In addition, the authors acknowledge STEM CELLS Translational Medicine journal and AlphaMed Press for permitting the adaptation of previously published figures (Llucià-Valldeperas, *et al.*30). The development of this prototype and the design of the protocol were supported by Ministerio de Educación y Ciencia (SAF 2008-05144), Ministerio de Economía y Competitividad (SAF 2014-59892), the European Commission 7th Framework Programme (RECATABI, NMP3-SL-2009-229239), Fundació La Marató de TV3 (080330, 201516, 201502), and Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE; 06-00001396-15).

**DISCLOSURES:**

The authors have nothing to disclose, except that the stimulation device and protocol were previously patented (WO-2013185818-A1, WO-2017125159-A1).

**REFERENCES:**

1. McDonough, P.M., Glembotski, C.C. Induction of atrial natriuretic factor and myosin light chain-2 gene expression in cultured ventricular myocytes by electrical stimulation of contraction. *Journal of Biological Chemistry*. **267**, 11665-11668 (1992).
2. Tandon, N. *et al.* Electrical stimulation systems for cardiac tissue engineering. *Nature* *Protocols*. **4**, 155-173 (2009).
3. Serena, E. *et al.* Electrical stimulation of human embryonic stem cells: cardiac differentiation and the generation of reactive oxygen species. *Experimental Cell Research*. **315**, 3611-3619 (2009).
4. Tandon, N. *et al.* Optimization of electrical stimulation parameters for cardiac tissue engineering. *Journal of Tissue* *Engineering and Regenerative Medicine*. **5**, E115-E125 (2011).
5. Zhang, X., Wang, Q., Gablaski, B., Lucchesi, P., Zhao, Y. A microdevice for studying intercellular electromechanical transduction in adult cardiac myocytes. *Lab on a Chip*. **13**, 3090-3097 (2013).
6. Chan, Y.C. *et al.* Electrical stimulation promotes maturation of cardiomyocytes derived from human embryonic stem cells. *Journal of Cardiovascular Translational Research*. **6**, 989-999 (2013).
7. Pietronave, S. *et al.* Monophasic and biphasic electrical stimulation induces a precardiac differentiation in progenitor cells isolated from human heart. *Stem Cells and Development*. **23**, 888-898 (2014).
8. Pavesi, A. *et al.* Electrical conditioning of adipose-derived stem cells in a multi-chamber culture platform. *Biotechnology and Bioengineering*. **111**, 1452-1463 (2014).
9. Baumgartner, S. *et al.* Electrophysiological and morphological maturation of murine fetal cardiomyocytes during electrical stimulation *in vitro*. *Journal of Cardiovascular Pharmacology and Therapeutics*. **20**, 104-112 (2015).
10. Llucià-Valldeperas, A. *et al.* Electrical stimulation of cardiac adipose tissue-derived progenitor cells modulates cell phenotype and genetic machinery. *Journal of Tissue* *Engineering and Regenerative Medicine*. **9** (11), E76-E83 (2015).
11. Llucià-Valldeperas, A. *et al.* Physiological conditioning by electric field stimulation promotes cardiomyogenic gene expression in human cardiomyocyte progenitor cells. *Stem Cell Research and Therapy*. **5**, 93 (2014).
12. Radisic, M. *et al.* Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. *Proceedings of the National Academy of Sciences of the United States of America*. **101** (52), 18129-34 (2004).
13. Fink, C. *et al.* Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement. *FASEB* *Journal*. **14**, 669-679 (2000).
14. Zimmermann, W.H. *et al.* Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. *Nature Medicine*. **12** (4), 452-8 (2006).
15. Birla, R.K., Huang, Y.C., Dennis, R.G. Development of a novel bioreactor for the mechanical loading of tissue-engineered heart muscle. *Tissue Engineering*. **13**, 2239-2248 (2007).
16. Salameh, A. *et al.* Cyclic mechanical stretch induces cardiomyocyte orientation and polarization of the gap junction protein connexin43. *Circulation Research*. **106**, 1592-1602 (2010).
17. Galie, P.A., Stegemann, J.P. Simultaneous application of interstitial flow and cyclic mechanical strain to a three-dimensional cell-seeded hydrogel. *Tissue Engineering Part C: Methods*. **17** (5), 527-536 (2011).
18. Leychenko, A., Konorev, E., Jijiwa, M., Matter, M.L. Stretch-induced hypertrophy activates NFkB-mediated VEGF secretion in adult cardiomyocytes. *PLoS One*. **6**, e29055 (2011).
19. Tulloch, NL. *et al.* Growth of engineered human myocardium with mechanical loading and vascular coculture. *Circulation Research*. **109**, 47-59 (2011).
20. Mihic, A. *et al.* The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. *Biomaterials*. **35**, 2798-2808 (2014).
21. Llucià-Valldeperas, A. *et al.* Unravelling the effects of mechanical physiological conditioning on cardiac adipose tissue-derived progenitor cells *in vitro* and in silico. *Scientific Reports*. **8**, 499 (2018).
22. Stoppel, W.L., Kaplan, D.L., Black 3rd, L.D. Electrical and mechanical stimulation of cardiac cells and tissue constructs. *Advanced Drug Delivery Reviews*. **96**, 135-155 (2016).
23. Nunes, S.S. *et al.* Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. *Nature Methods.* **10**, 781-787 (2013).
24. Barash, Y. *et al.* Electric field stimulation integrated into perfusion bioreactor for cardiac tissue engineering. *Tissue Engineering Part C: Methods*. **16**, 1417-1426 (2010).
25. Maidhof, R. *et al.* Biomimetic perfusion and electrical stimulation applied in concert improved the assembly of engineered cardiac tissue. *Journal of Tissue* *Engineering and Regenerative Medicine*. **6**, e12-e23 (2012).
26. Feng, Z. *et al.* An electro-tensile bioreactor for 3-D culturing of cardiomyocytes. A bioreactor system that simulates the myocardium’s electrical and mechanical response *in vivo*. *IEEE Engineering in Medicine and Biology Magazine.* **24** (4), 73-79 (2005).
27. Wang, B. *et al.* Myocardial scaffold-based cardiac tissue engineering: application of coordinated mechanical and electrical stimulations. *Langmuir*. **29** (35), 11109-11117 (2013).
28. Morgan, K.Y., Black 3rd, L.D. Mimicking isovolumic contraction with combined electromechanical stimulation improves the development of engineered cardiac constructs. *Tissue Engineering Part A*. **20** (11-12), 1654-1667 (2014).
29. Godier-Furnémont, A.F. *et al.* Physiologic force-frequency response in engineered heart muscle by electromechanical stimulation. *Biomaterials*. **60**, 82-91 (2015).
30. Llucià-Valldeperas, A. *et al.* Electromechanical Conditioning of Adult Progenitor Cells Improves Recovery of Cardiac Function After Myocardial Infarction. *Stem Cell* *Translational Medicine*. **6** (3), 970-981 (2017).
31. Ronaldson-Bouchard, K. *et al.* Advanced maturation of human cardiac tissue grown from pluripotent stem cells. *Nature*. **556** (7700), 239-243 (2018).
32. Gelmi, A. *et al.* Direct Mechanical Stimulation of Stem Cells: A Beating Electromechanically Active Scaffold for Cardiac Tissue Engineering. *Advanced Healthcare Materials*. **5** (12), 1471-1480 (2016).
33. Poulin, A. *et al.* An ultra-fast mechanically active cell culture substrate. *Scientific* *Reports*. **8** (1), 9895 (2018).
34. Bayes-Genis, A. *et al.* Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents. *Journal of Molecular and Cellular Cardiology*. **49** (5), 771-780 (2010).
35. Bagó, J.R. *et al.* Bioluminescence imaging of cardiomyogenic and vascular differentiation of cardiac and subcutaneous adipose tissue-derived progenitor cells in fibrin patches in a myocardium infarct model. *International Journal of Cardiology*. **169**, 288-295 (2013).
36. Zimmermann, W.H. *et al.* Tissue engineering of a differentiated cardiac muscle construct. *Circulation Research*. **90** (2), 223-230 (2002).
37. Rosell Ferrer, F.X., Sánchez Terrones, B., Bragós Bardia, R., Bayés Genís, A., Llucià Valldeperas, A. Methods and devices for mechanical and electrical stimulation of stem cell monolayer and 3d cultures for tissue engineering applications. WO/2013/185818. Barcelano, Spain (2013).
38. Bayés Genís, A., Llucià Valldeperas, A., Soler Botija, C., Bragós Bardia, R., Rosell Ferrer, F.X. Method for Conditioning Stem Cells. WO/2017/125159. Barceleno, Spain (2017).
39. Roura, S., Gálvez-Montón, C., Bayes-Genis, A. Myocardial healing using cardiac fat. *Expert Review of Cardiovascular Therapy*. **16** (4), 305-311 (2018).
40. Zhang, Y.M., Hartzell, C., Narlow, M., Dudley Jr., S.C. Stem cell-derived cardiomyocytes demonstrate arrhythmic potential. *Circulation*. **106** (10), 1294-1299 (2002).
41. Liu, J., Fu, J.D., Siu, C.W., Li, R.A. Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation. *Stem Cells*. **25** (12), 3038-3044 (2007).
42. Wipff, P.J. *et al.* The covalent attachment of adhesion molecules to silicone membranes for cell stretching applications. *Biomaterials*. **30** (9), 1781-1789 (2009).
43. Kim, C. iPSC technology--Powerful hand for disease modeling and therapeutic screen. *Biochemistry and Molecular Biology Reports.* **48** (5), 256-265 (2015).
44. Ronaldson-Bouchard, K., Vunjak-Novakovic, G. Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. *Cell Stem Cell*. **22** (3), 310-324 (2018).
45. Bruyneel, A.A., McKeithan, W.L., Feyen, D.A., Mercola, M. Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease? *Current Opinion in* *Pharmacology*. **42**, 55-61 (2018).
46. Farley, A., Johnstone, C., Hendry, C., McLafferty, E. Nervous system: part 1. *Nursing Standard*. **28** (31), 46-51 (2014).
47. Brotto, M., Bonewald, L. Bone and muscle: Interactions beyond mechanical. *Bone*. **80**, 109-114 (2015).
48. Park, S.J. *et al.* Neurogenesis Is Induced by Electrical Stimulation of Human Mesenchymal Stem Cells Co-Cultured With Mature Neuronal Cells. *Macromolecular Bioscience*. **15** (11), 1586-1594 (2015).
49. Vianney, J.M., Miller, D.A., Spitsbergen, J.M. Effects of acetylcholine and electrical stimulation on glial cell line-derived neurotrophic factor production in skeletal muscle cells. *Brain Research*. **1588**, 47-54 (2014).
50. Shima, A., Morimoto, Y., Sweeney, H.L., Takeuchi, S. Three-dimensional contractile muscle tissue consisting of human skeletal myocyte cell line. *Experimental Cell Research*. **370** (1), 168-173 (2018).